Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1J4CI
|
|||
| Drug Name |
Zenocutuzumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [1] | |
| Company |
Merus
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health. | |||
| REF 2 | Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.